Depakote sales continue to drift for Abbott as Humira rebounds
This article was originally published in Scrip
Executive Summary
Abbott Laboratories' second-quarter profits have slipped by 3% on a blend of charges and declining sales of Depakote (divalproex sodium). Net earnings of $1.29 billion were in line with analysts' expectations as the anti-epilepsy drug steadily lost market share to generics.